TLPPF (TLPPF) Stock Price & Analysis
TLPPF (TLPPF) rose 0.00% to USD 10.99 as of September 9, 2026 at 21:21 UTC, according to Nexqual real-time market data.
TLPPF last closed at USD 10.99; the session ranged USD 11.5–11.5 on volume of 770 shares. Market capitalization is $3.73B, with a 52-week range of USD 5.91–12.5 (PNK). Source: Nexqual, September 9, 2026 at 21:21 UTC.
Key Statistics (as of September 9, 2026 at 21:21 UTC)
| Price | USD 10.99 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.99 |
| Open | USD 11.5 |
| Day Range | USD 11.5 – 11.5 |
| 52-Week Range | USD 5.91 – 12.5 |
| Volume | 770 shares |
| Market Cap | $3.73B |
| Exchange | PNK |
Technical Analysis (TLPPF)
Nexqual's technical model rates TLPPF "NEUTRAL" based on 3 bullish and 2 bearish signals across 126 daily candles, as of September 9, 2026 at 21:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.53 (neutral) |
| vs SMA50 | Above (USD 10.95) |
| MACD | 0.1 (positive) |
Analyst Ratings (TLPPF)
Wall Street analysts rate TLPPF "None", per Nexqual as of September 9, 2026 at 21:21 UTC.
| Consensus Rating | None |
|---|
Earnings (TLPPF)
| Next Earnings Date | 2026-08-19 |
|---|---|
| Revenue Estimate | $347.32M |
Source: Nexqual, September 9, 2026 at 21:21 UTC.
Financials & Fundamentals (TLPPF)
| Total Revenue | $890.79M |
|---|---|
| Revenue Growth (YoY) | +22.30% |
| Gross Margin | +47.57% |
| Operating Margin | +9.71% |
| Profit Margin | +3.76% |
| ROE | +7.36% |
| Debt / Equity | 118.9 |
| Current Ratio | 2.01 |
| Total Cash | $251.91M |
| Total Debt | $579.86M |
| Free Cash Flow | $-62.60M |
Source: Nexqual, September 9, 2026 at 21:21 UTC.
Financial Health Score (TLPPF)
Nexqual rates TLPPF's overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 21:21 UTC.
| Growth | Strong — Revenue +53% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 48%, operating 10% |
| Balance Sheet | Mixed — $252M cash vs $580M debt |
| Cash Flow | Weak — FCF negative: -$63M, burning cash |
| Efficiency | Mixed — ROE 7%, ROA 2.7% |
Ownership (TLPPF)
| Insider Ownership | +16.90% |
|---|---|
| Institutional Ownership | +32.65% |
| Shares Outstanding | 339.78M |
| Float | 273.62M |
Source: Nexqual, September 9, 2026 at 21:21 UTC.
Leadership (TLPPF)
TLPPF is led by Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D. (age 49), Co-Founder, MD, Group CEO & Executive Director, per Nexqual as of September 9, 2026 at 21:21 UTC.
| Co-Founder, MD, Group CEO & Executive Director | Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D. (age 49) |
|---|---|
| Group Chief Financial Officer | Darren Smith B.Bus., FCPA (age 60) |
| Group Chief Operating Officer | Darren Patti Pharm.D. (age 52) |
| Senior Vice President of Corporate Communications & Investor Relations | Kyahn Williamson B.A. |
| Senior Vice President of Global People & Culture | Meredith Crowe BDES |
Major Backers & Investors (TLPPF)
Notable institutional backers of TLPPF include DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series, Charles Schwab, according to Nexqual as of September 9, 2026 at 21:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series | 0.27% |
| Charles Schwab | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.2% |
| State Street | 0.2% |
Source: Nexqual, September 9, 2026 at 21:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IVBXF | Innovent Biologics Inc. | USD 13.19 | ▲ 0.57% |
| ZLDPF | Zealand Pharma A/S | USD 46.38 | ▼ 2.66% |
| PTCHF | PureTech Health PLC | USD 1.65 | ▲ 5.5% |
| UCBJY | UCB S.A. | USD 118.75 | ▼ 2.96% |
| WXIBF | Wuxi Biologics (Cayman) Inc | USD 6.23 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 21:21 UTC. This page is informational and not investment advice.